Malignant hyperpyrexia.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000768:Anesthesia, General / Q000009:adverse effects; D000818:Animals; D001639:Bicarbonates / Q000627:therapeutic use; D002110:Caffeine / Q000494:pharmacology; D003402:Creatine Kinase / Q000097:blood; D006019:Glycolysis; D006801:Humans; D008274:Magnesium / Q000378:metabolism; D008305:Malignant Hyperthermia / Q000453:epidemiology / Q000209:etiology / Q000235:genetics; D009119:Muscle Contraction / Q000187:drug effects; D009135:Muscular Diseases / Q000150:complications; D011343:Procaine / Q000627:therapeutic use; D011379:Prognosis; D013552:Swine
D001639:Bicarbonates; D002110:Caffeine; D011343:Procaine; D000255:Adenosine Triphosphate; D003402:Creatine Kinase; D008274:Magnesium